Inflammatory Bowel Disease(IBD): New Trends in Diagnosis and Management—2nd Edition

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1221

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterology, Fakeeh University Hospital, Dubai, United Arab Emirates
Interests: inflammatory bowel disease; functional bowel disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The prevalence of inflammatory bowel diseases is progressively increasing worldwide, affecting approximately six million patients. It is well established that the IBD-associated tissue damage process is induced by an exaggerated immune response against luminal antigens and that it is affected by genetic predisposition and environmental factors, although etiology remains unclear. An early and accurate diagnosis may still be a challenge, and there is a lack of “gold-standard” treatment; this may impact future management through a variety of complications and disabilities. This Special Issue will review all the diagnostic modalities with a focus on possible management-related consequences in order to achieve more precise and individualized care.

Dr. Vito Annese
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1502 KiB  
Review
Endoscopy in IBD: When and How?
by Marco Daperno
Diagnostics 2023, 13(22), 3423; https://doi.org/10.3390/diagnostics13223423 - 10 Nov 2023
Cited by 2 | Viewed by 1059
Abstract
Endoscopy is an essential tool supporting inflammatory bowel disease diagnosis, and ileocolonoscopy is essential to the diagnostic process because it allows for histological sampling. A decent description of endoscopic lesions may lead to a correct final diagnosis up to 89% of the time. [...] Read more.
Endoscopy is an essential tool supporting inflammatory bowel disease diagnosis, and ileocolonoscopy is essential to the diagnostic process because it allows for histological sampling. A decent description of endoscopic lesions may lead to a correct final diagnosis up to 89% of the time. Moreover, endoscopy is key to evaluating endoscopic severity, which in both Crohn’s disease and ulcerative colitis is associated with worse disease outcomes (e.g., more frequent advanced therapy requirements or more frequent hospitalizations and surgeries). Endoscopic severity should be reported according to validated endoscopic scores, such as the Mayo endoscopic subscore (MES) or the ulcerative colitis endoscopic index of severity (UCEIS) for ulcerative colitis, the Rutgeerts score for postoperative Crohn’s recurrence, and the Crohn’s disease endoscopic index of severity (CDEIS) or the simplified endoscopic score for Crohn’s disease (SES-CD) for luminal Crohn’s disease activity. The measuring of endoscopic activity has become a regulatory agency requirement to increase the objective evaluation of disease activity and drug response. In recent years, the central reviewing of endoscopic videos has become a standard for clinical trials. However, the adjudication paradigm and the type of endoscopic reading may substantially affect trial outcomes, and the reproducibility of all endoscopic scores is not perfect as they require the interpretation of intrinsically subjective images. This paper reviews and discusses the available evidence on inflammatory bowel disease endoscopy. Full article
Show Figures

Figure 1

Back to TopTop